Beyond RAAS blockade, sodium–glucose co-transporter 2 (SGLT2) inhibitors—now widely employed in HF management—have emerged as promising agents with pleiotropic cardioprotective effects [187]. Here, SLC5A2 is linked to hydrops fetalis.